Rheumatoid Arthritis
Early intervention is important
Published in Immunotherapy Weekly, April 24th, 2002
In a recent study, researchers found that the delay of treatment to patients with early rheumatoid arthritis (RA) significantly decreases the ability of traditional single-drug therapy to combat the disease's debilitating symptoms. According to the study, which is published in the April 2002 issue of Arthritis & Rheumatism, a single-drug strategy is insufficient to achieve remission and prevent joint damage unless initiated at the onset of RA symptoms.
"Spontaneous remissions are rare in established RA and in most cases the disease shows a resistant course with progressive joint damage and increasing disability," observed chief researcher Timo Mottonen, MD, PhD,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2002-04-24)
More Articles from Immunotherapy Weekly
- Escherichia Coli
MGH study identifies key immune system molecule - Allergy Medicine
Experimental treatment for hay fever is safe, effective, and fast - Asthma
New therapy may reverse asthmatic condition in mice - Stem Cell Transplantation
Campath-1G transiently depletes host dendritic cells - Tuberculosis
Researchers identify immune response to TB infection - Acute Leukemia
Study finds that marrow transplantation using unrelated donors should be considered for children - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
